TY - JOUR
T1 - Walking-related digital mobility outcomes as clinical trial endpoint measures
T2 - Protocol for a scoping review
AU - Polhemus, Ashley Marie
AU - Bergquist, Ronny
AU - Bosch De Basea, Magda
AU - Brittain, Gavin
AU - Buttery, Sara Catherine
AU - Chynkiamis, Nikolaos
AU - Dalla Costa, Gloria
AU - Delgado Ortiz, Laura
AU - Demeyer, Heleen
AU - Emmert, Kirsten
AU - Garcia Aymerich, Judith
AU - Gassner, Heiko
AU - Hansen, Clint
AU - Hopkinson, Nicholas
AU - Klucken, Jochen
AU - Kluge, Felix
AU - Koch, Sarah
AU - Leocani, Letizia
AU - Maetzler, Walter
AU - Micó-Amigo, M. Encarna
AU - Mikolaizak, A. Stefanie
AU - Piraino, Paolo
AU - Salis, Francesca
AU - Schlenstedt, Christian
AU - Schwickert, Lars
AU - Scott, Kirsty
AU - Sharrack, Basil
AU - Taraldsen, Kristin
AU - Troosters, Thierry
AU - Vereijken, Beatrix
AU - Vogiatzis, Ioannis
AU - Yarnall, Alison
AU - Mazza, Claudia
AU - Becker, Clemens
AU - Rochester, Lynn
AU - Puhan, Milo Alan
AU - Frei, Anja
N1 - Publisher Copyright:
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2020/7/19
Y1 - 2020/7/19
N2 - Introduction Advances in wearable sensor technology now enable frequent, objective monitoring of real-world walking. Walking-related digital mobility outcomes (DMOs), such as real-world walking speed, have the potential to be more sensitive to mobility changes than traditional clinical assessments. However, it is not yet clear which DMOs are most suitable for formal validation. In this review, we will explore the evidence on discriminant ability, construct validity, prognostic value and responsiveness of walking-related DMOs in four disease areas: Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease and proximal femoral fracture. Methods and analysis Arksey and O'Malley's methodological framework for scoping reviews will guide study conduct. We will search seven databases (Medline, CINAHL, Scopus, Web of Science, EMBASE, IEEE Digital Library and Cochrane Library) and grey literature for studies which (1) measure differences in DMOs between healthy and pathological walking, (2) assess relationships between DMOs and traditional clinical measures, (3) assess the prognostic value of DMOs and (4) use DMOs as endpoints in interventional clinical trials. Two reviewers will screen each abstract and full-text manuscript according to predefined eligibility criteria. We will then chart extracted data, map the literature, perform a narrative synthesis and identify gaps. Ethics and dissemination As this review is limited to publicly available materials, it does not require ethical approval. This work is part of Mobilise-D, an Innovative Medicines Initiative Joint Undertaking which aims to deliver, validate and obtain regulatory approval for DMOs. Results will be shared with the scientific community and general public in cooperation with the Mobilise-D communication team. Registration Study materials and updates will be made available through the Center for Open Science's OSFRegistry (https://osf.io/k7395).
AB - Introduction Advances in wearable sensor technology now enable frequent, objective monitoring of real-world walking. Walking-related digital mobility outcomes (DMOs), such as real-world walking speed, have the potential to be more sensitive to mobility changes than traditional clinical assessments. However, it is not yet clear which DMOs are most suitable for formal validation. In this review, we will explore the evidence on discriminant ability, construct validity, prognostic value and responsiveness of walking-related DMOs in four disease areas: Parkinson's disease, multiple sclerosis, chronic obstructive pulmonary disease and proximal femoral fracture. Methods and analysis Arksey and O'Malley's methodological framework for scoping reviews will guide study conduct. We will search seven databases (Medline, CINAHL, Scopus, Web of Science, EMBASE, IEEE Digital Library and Cochrane Library) and grey literature for studies which (1) measure differences in DMOs between healthy and pathological walking, (2) assess relationships between DMOs and traditional clinical measures, (3) assess the prognostic value of DMOs and (4) use DMOs as endpoints in interventional clinical trials. Two reviewers will screen each abstract and full-text manuscript according to predefined eligibility criteria. We will then chart extracted data, map the literature, perform a narrative synthesis and identify gaps. Ethics and dissemination As this review is limited to publicly available materials, it does not require ethical approval. This work is part of Mobilise-D, an Innovative Medicines Initiative Joint Undertaking which aims to deliver, validate and obtain regulatory approval for DMOs. Results will be shared with the scientific community and general public in cooperation with the Mobilise-D communication team. Registration Study materials and updates will be made available through the Center for Open Science's OSFRegistry (https://osf.io/k7395).
KW - Parkinson-s disease
KW - chronic airways disease
KW - geriatric medicine
KW - multiple sclerosis
KW - orthopaedic & trauma surgery
KW - telemedicine
UR - http://www.scopus.com/inward/record.url?scp=85088351434&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2020-038704
DO - 10.1136/bmjopen-2020-038704
M3 - Review article
C2 - 32690539
AN - SCOPUS:85088351434
SN - 2044-6055
VL - 10
JO - BMJ Open
JF - BMJ Open
IS - 7
M1 - e038704
ER -